Previous 10 | Next 10 |
Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the appointment of Marc Malandro, Ph.D., to the company’s scientific advisory board. Dr. Malandro, a...
EAGAN, Minn., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) today announced the appointment of Marc Malandro, Ph.D., to the company’s Scientific Advisory Board where he will serve alongside other key thought leaders in their respective fields to guide the c...
Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has closed on two direct offerings. The offerings, which were available concurrently, were with dif...
EAGAN, Minn., May 18, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discover...
Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its entry into definitive agreements with several institutional investors for the issuance and sale o...
Predictive Oncology (NASDAQ:POAI) enters issuance and sale agreement regarding certain stock purchase warrants, that are expected to result in gross proceeds totaling ~$7.2M. In the first offering, company has entered into definitive agreements with several institutional investors f...
EAGAN, Minn., May 16, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discover...
Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has released financial results from its first quarter, the period ending March 31, 2022. Highlights from the report i...
Predictive Oncology press release (NASDAQ:POAI): Q1 GAAP EPS of -$0.05 misses by $0.01. Revenue of $0.31M (+10.7% Y/Y) misses by $0.69M. For further details see: Predictive Oncology GAAP EPS of -$0.05 misses by $0.01, revenue of $0.31M misses by $0.69M
EAGAN, Minn., May 12, 2022 (GLOBE NEWSWIRE) -- The financial results from the first quarter we believe depicts a solid potential for growth in the upcoming period, in accordance with the report by Predictive Oncology Inc. (NASDAQ: POAI) today, disclosing the results for the quarter ende...
News, Short Squeeze, Breakout and More Instantly...
Predictive Oncology Inc. Company Name:
POAI Stock Symbol:
NASDAQ Market:
Predictive Oncology Inc. Website:
Predictive Oncology (NASDAQ: POAI) , a leader in AI-driven drug discovery and biologics, today announced the introduction of a new technology designed to express functional and stable G-Protein Coupled Receptors (“GPCRs”). GPCRs are cell surface membrane receptors believed to play a...
Company files expansive intellectual property protection for “Membrane Protein Factory” to produce purified and biologically active membrane proteins for drug development External sources value annual US GPCR market at nearly $3.5 billion in 2022, growing more than 5% annu...
Predictive Oncology (NASDAQ: POAI) , a leader in AI-driven drug discovery and biologics, today announced the availability of its unique 3D cell culture model to advance cancer drug discovery and enable future drug development. More closely mimicking human tissue architecture than traditional 2D a...